Cancer-related fatigue
Conditions
Interventions
Treatment group:Conventional treatment + Shengbai oral liquid
Control group:Conventional treatment
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The estimated survival period is more than 3 months, aged =18 years old, male or female; 2.Patients with malignant tumor diagnosed by pathology or cytology, and have undergone =1 cycle of chemotherapy, targeted therapy, immunotherapy or radiation therapy; 3.Patients who meet the diagnostic criteria of cancer-related fatigue (refer to the diagnostic criteria of cancer-related fatigue proposed in 2018 NCCN Clinical Practice Guidelines), and Piper fatigue scale score=4 points; 4.Clear consciousness, can communicate normally, and can cooperate with medical staff to complete questionnaires and physical examinations and assessments; 5.Patients who voluntarily accept the treatment of this clinical trial, who can insist on follow-up visits as prescribed by the doctor, and have good compliance.
Exclusion criteria
Exclusion criteria: 1.Patients with severe primary diseases of heart, lung, liver, kidney, hematopoietic system, endocrine system, etc. and the condition is unstable [severe liver and kidney dysfunction (ALT and AST are 3 times higher than ULN, Cr and BUN are 1.5 times higher than ULN), hemoglobin <80 g/L or platelets <50×109/L or neutrophils <1.0×109/L, NYHA grade IV, multiple organ failure, cachexia, etc.] 2.Patients with other diseases that may cause fatigue, such as muscular dystrophy, muscle weakness caused by uncontrolled endocrine, metabolic diseases or neurological diseases; 3.Patients who use steroids systemically due to chronic skin rashes, autoimmune diseases, etc. (regular doses of dexamethasone are allowed for antiemetic and other treatments); 4.TCM syndrome differentiation are yin deficiency and fire exuberance syndrome and heat toxic syndrome, and those with bleeding tendency; 5.Patients who are unable to cooperate, such as those with neurological or psychiatric disorders, or those who are unwilling to cooperate; 6.Patients who have participated or currently participating in other clinical trials within 1 months; 7.People who are allergic to the drugs used in this clinical trial, or with allergic constitution, or allergic to multiple drugs; 8.Pregnant or breastfeeding women, or those of childbearing age (including men) who are unwilling to take contraceptive measures; 9.Patients who are judged by researchers to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total score of Piper fatigue scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total score of Piper fatigue scale;The number of chemotherapy cycles completed;Total number of white blood cells, neutrophils, platelets and red blood cells;Total score of traditional Chinese medicine symptoms (MDASI-TCM criteria);Subgroup analysis: (1) Patients with normal white blood cells. (2) Patients with leukopenia: ?patients who have previously received effective white blood cell count-increasing treatments; ?patients who have previously received ineffective white blood cell count-increasing treatments.; | — |
Countries
China
Contacts
Public ContactLong Shunqin
Outcome results
None listed